Lipid Control Post Coronary Artery Bypass Graft: One Year Follow-Up of a Middle-Eastern Cohort

Lipid Control Post Coronary Artery Bypass Graft: One Year Follow-Up of a Middle-Eastern Cohort

Data on patient characteristics and provider practices in the management of lipids per the new guidelines in specific secondary prevention patients in the Middle East is limited. To explore patient characteristics and lipid management practices according to the new cholesterol guidelines in secondar...

Full description

Saved in:
Bibliographic Details
Published in:Global heart Vol. 15; no. 1; p. 12
Main Authors: Atallah, Bassam, Khaddage, Ramzi, Sadik, Ziad G, Mallah, Saad I, Lee-St John, Terrence J, Alfardan, Shamsah, Traina, Mahmoud I, Almahmeed, Wael
Format: Journal Article
Language:English
Published: England Ubiquity Press 10-02-2020
Subjects:
ascvd
Biomarkers - blood
cabg
Coronary Artery Bypass - methods
Coronary Artery Disease - blood
Coronary Artery Disease - surgery
Female
Follow-Up Studies
Humans
hyperlipidemia
lipid-lowering-medications
Lipids - blood
Male
Middle Aged
middle-east
Original Research
Prognosis
Retrospective Studies
secondary prevention
statins
Time Factors
United Arab Emirates - epidemiology
United Arab Emirates
ASCVD
Hyperlipidemia
Middle-East
Secondary Prevention
CABG
Lipid-Lowering-Medications
Statins
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Data on patient characteristics and provider practices in the management of lipids per the new guidelines in specific secondary prevention patients in the Middle East is limited. To explore patient characteristics and lipid management practices according to the new cholesterol guidelines in secondary prevention patients, up to one year following discharge for coronary artery bypass graft surgery (CABG). A retrospective chart review of patients discharged post CABG between February 2017 and February 2018 at a quaternary care centre in the Middle East. Patients were characterized by baseline demographics, comorbidities, and use of lipid lowering medications. 189 patients were included in the analysis. Most were diabetic (70.9%) and classified as very high risk per the ACC/AHA guidelines (84.1%) and as extremely high risk per the AACE guidelines (85.2%). Most patients (93.1%) were discharged on high intensity statin. About one third (28.6%) were never seen or only followed once within the first 2 weeks post discharge. Of those who continued to follow up beyond 3 months and within 1 year of discharge (44.4%), about half (51.2%) had follow-up lipid panels performed. Patients who followed up and were seen by a cardiologist were five times more likely to have lipid panels ordered than those seen solely by a CT surgeon. Of those with follow-up lipid panels beyond 3 months: 59.3% achieved LDL goal of <70 mg/dL and 29% achieved LDL <55 mg/dL based on their respective goals. Most patients undergoing CABG in a quaternary care centre in the Middle East are high risk ASCVD. Nonetheless, lipid goals are not commonly achieved nor routinely monitored. Providers will need to transition from the previous risk stratification and statin-only focused approach to adopt the most recent guidelines.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2211-8160
2211-8179
2211-8179
DOI:10.5334/gh.530